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E-mail address: sbhwang@hallym.ac.kr (S.B. HwanInterferon (IFN) response rate in hepatitis C virus (HCV) patients has been varied with genotypes. In
this study, we investigated the effects of HCV NS5A protein on IFN resistance and compared the
genotypic differences of NS5A. We showed that IFN-a-, poly I:C-, and Sendai virus-induced ISRE tran-
scriptional activities were inhibited by both genotype 1b and 2a NS5A protein. We demonstrated
that not only genotype 1b but also genotype 2a NS5A exerted the similar extent of IFN-a-induced
antiviral activity. We showed that NS5A derived from both genotype 1b and 2a showed no signiﬁ-
cant differential IFN responses as seen in HCV patients. These data imply that some other host factor
may be involved in genotypic differences of IFN antagonism in HCV patients.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction Type 1 IFNs (IFNa/b) evoke innate immune responses and re-Hepatitis C virus (HCV) is a major cause of chronic liver disease,
which often leads to liver cirrhosis and hepatocellular carcinoma
[1]. More than 170 million people worldwide are infected with
HCV.HCV is amemberof the Flaviviridae family and contains a single
stranded, positive-sense RNA genome of 9600 nucleotides in
length. The HCV genome encodes a single polyprotein precursor of
approximately 3010 amino acids that is cleaved by both cellular
signal peptidase and viral protease to generate three structural
and seven non-structural proteins [2]. Core, E1, and E2 proteins
are viral structural proteins, and p7, NS2, NS3, NS4A/B, and NS5A/
Barenon-structural proteins. Thenon-structural 5A (NS5A) is amul-
tifunctional phosphoprotein consisting of 447 amino acids residues.
NS5Amay lead to pleiotropic responses, including regulation of cell
growth and cellular signaling pathways [3,4]. NS5A is implicated in
antiviral resistance to interferon (IFN). NS5A has the IFN sensitivity-
determining region (ISDR). NS5A interacts with the IFN-inducible
double-stranded RNA-activated protein kinase PKR through the
ISDR and functions as a repressor of PKR [5]. However, the involve-
ment of ISDR ofNS5A inHCV antiviral responses is still controversial
[6]. It has been reported previously that HCV E2 protein was also
involved in IFN-induced antiviral response by inhibiting the PKR
activity [7].chemical Societies. Published by E
ructural 5A; ISGs, interferon-
g).move the viruses by activating the IFN stimulated genes (ISGs)
[8]. The JAK-STAT is an important signaling pathway in immune re-
sponses. Once type 1 IFNs bind to their cellular receptors, IFN-al-
pha receptor 1 (IFNAR1) becomes activated by phosphorylation.
The activated receptor subsequently stimulates Janus kinases
(JAKs). JAKs have a tyrosine kinase activity that leads to phosphor-
ylation of signal transducer and activator of transcription (STATs) 1
and 2 [9]. The phosphorylated STAT1 and STAT2 form either homo-
or hetero-dimer that binds further with either IRF9 or P48. The
resulting IFN-stimulated gene factor 3 (ISGF3) complex interacts
with the IFN-stimulated response elements (ISREs) sequences in
the promoter region and thus stimulates ISGs [10].
To elucidate how genotypic difference of HCV occurs in IFN
treatment, we investigated the effects of NS5A protein on antiviral
activities using IFN, poly I:C, and Sendai virus treatments. Our data
demonstrate that NS5A inhibits IFN signaling via JAK-STAT path-
way and induction of interleukin-8/CXCL-8 (IL-8) (also referred
to as CXCL-8). Nevertheless, NS5A derived from genotype 1b and
2a exerted no signiﬁcant genotypic differences in the responses
to IFN, poly I:C, and Sendai virus treatments.2. Materials and methods
2.1. Plasmid constructions
cDNA encoding HCV NS5A (genotype 2a) was ampliﬁed by PCR
using the JFH-1 clone of HCV [11] as a template and subcloned intolsevier B.V. All rights reserved.
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Myc-NS3, Myc-NS4B, and Myc-NS5B expression plasmids were
subcloned into the pEF6/Myc-His vector. NS5A deletion mutants
were generated by PCR and subcloned into the pEF6/Myc-His
expression vector. ISRE-luc vector was kindly provided by Dr. S.
Goodbourn (St George’s University of London).
2.2. Cell culture
Huh7 cells, HEK293 cells and HEK293T cells were grown as de-
scribed previously [12].
2.3. Luciferase reporter gene assay
HEK293T, Huh7 and NS5A stable cells were transfected with
0.2 lg of ISRE-luciferase (ISRE-luc) reporter plasmid and 0.1 lg of
pCH110 reference plasmid (Amersham Biosciences) using PEI.
Luciferase and b-galactosidase assays were performed as described
previously [13].
2.4. Immunoblot analysis
Cell lysates were prepared and immunoblotted as described
previously [12].
2.5. Cytoplasmic and nuclear fractionation
Both cytoplasmic and nuclear fractions were prepared as we re-
ported previously [12]. Equal amounts of protein were subjected to
immunoblot analysis to verify cytosolic and nuclear fractions using
either anti-GAPDH or anti-B23 antibodies.
2.6. CXCL-8/IL-8 immunoassay
Culture supernatants were harvested from the vector and NS5A
stable cells after 36 h incubation and the supernatants were di-
luted 100-fold with Calibrator Diluent RD5P supplied by Quantiki-
ne kit (D8000C, Human CXCL-8/IL-8 Immunoassay kit). IL-8 levels
were determined using an IL-8 immunoassay kit according to the
manufacturer’s instructions (R&D system).3. Results
3.1. NS5A protein derived from both genotype 1b and 2a inhibits IFN-
a-induced ISRE reporter activity
Because sustained virological response (SVR) rate to the IFN
therapy varied signiﬁcantly in HCV patients infected with differ-
ent genotypes, we compared IFN-induced ISRE reporter activity
between genotype 1b and 2a NS5A. For this purpose, Huh7 cells
were cotransfected with ISRE-luc reporter plasmid and empty
vector, 1b NS5A, 2a NS5A expression plasmid, individually.
Luciferase activities were then determined. Fig. 1A showed that
ISRE-luc reporter activity was activated by IFN-a treatment in
vector control cells. However, IFN-a-induced ISRE-luc reporter
activity was inhibited by both genotype 1b and 2a NS5A protein.
We further found that IFN-a-induced ISRE reporter activity
was inhibited by both genotype 1b and 2a NS5A protein in a
dose-dependent manner as shown in Fig. 1B. It was shown that
genotype 1b NS5A repressed ISRE transcriptional activity slightly,
but not signiﬁcantly, more than genotype 2a NS5A. As a control,
we performed the experiments using irrelevant proteins to exam-
ine whether these proteins also inhibited ISRE signaling. As shown
in Supplementary Fig. 1, neither NS4B nor NS5B inhibited ISRE
reporter activity.Poly I:C is an analog of double-stranded RNA, which provokes
type I interferon responses, including IFN-b production and ISRE
gene expression [10,14]. To further investigate whether Poly
I:C-induced ISRE-luc reporter activity was also modulated by
NS5A protein, Huh7 cells were transfected with ISRE-luc reporter
plasmid together with vector, 1b NS5A, 2a NS5A expression
plasmid, individually with or without poly I:C treatment, and then
luciferase activities were determined. As expected, ISRE transcrip-
tional activity was markedly increased by poly I:C in control
vector cells (Fig. 1C). Similar to IFN-a, Poly I:C-induced ISRE-luc
reporter activity was inhibited by NS5A protein. We also found
that the inhibitory effect of NS5A protein on Poly I:C-induced
ISRE gene expression between two genotypes was also insignif-
icant.
Since Sendai virus infection induces ISRE gene expression [14],
we investigated whether Sendai virus-induced ISRE-luc reporter
activity was also regulated by NS5A protein. Huh7 cells cotrans-
fected with ISRE-luc reporter plasmid and vector, 1b NS5A, 2a
NS5A expression plasmid, individually were infected with Sendai
virus for 6 h and then luciferase activities were determined.
Fig. 1D showed that Sendai virus-induced ISRE transcriptional
activity (lane 2) was also inhibited by NS5A protein of both
genotype 1b (lane 3) and 2a (lane 4). The inhibitory effect of
NS5A on Sendai virus-induced ISRE reporter activity showed no
signiﬁcant difference between two genotypes.
3.2. NS5A protein derived from both genotype 1b and 2a inhibits IFN-
a-induced STAT1 phosphorylation and its nuclear translocation
Stimulation of IFN-a signaling leads to the phosphorylation of
STAT1 protein. Phosphorylated STAT1 then forms ISGF3 complex
together with STAT2 and IRF9, and this complex is translocated
to the nucleus and induces ISRE gene expression [15]. To elucidate
the underlying mechanism of inhibitory role of NS5A in IFN sig-
naling, we investigated IFN-a-induced STAT1 phosphorylation in
cells expressing NS5A protein. Stable cells expressing 1b NS5A,
2a NS5A, and vector, respectively were treated with increasing
amounts of IFN-a for 12 h and then STAT1 phosphorylation level
was determined. NS5A is a key regulator of the type I IFN-induced
immune responses, and thereby NS5A strongly inhibits STAT1
activation in Huh7 cells. As shown in Fig. 2A, phosphorylation
level of STAT1 was increased in a dose-dependent manner of
IFN in vector stable cells (top panel). However, IFN-a-induced
STAT1 phosphorylation was signiﬁcantly inhibited by both 1b
and 2a NS5A proteins. Next, we investigated whether inhibition
of STAT1 phosphorylation by NS5A protein could interrupt nuclear
translocation of phosphorylated STAT1. Both cytosolic and nuclear
fractions prepared from stable cells either untreated or treated
with IFN-a were immunoblotted with anti-phospho-STAT1
antibody. In the absence of IFN-a treatment, STAT1 was not phos-
phorylated (Fig. 2B, left panel) and endogenous STAT1 expression
level was not affected by NS5A protein in all cells. However, IFN-a
stimulated both phosphorylation and nuclear translocation of
STAT1 protein in vector stable cells (Fig. 2B, lanes 1 and 4 in right
panel). On the other hand, IFN-a-induced phosphorylation and
nuclear translocation of STAT1 were dramatically inhibited in cells
expressing NS5A protein derived from both genotypes 1b and 2a
(Fig. 2B, lanes 5 and 6 in right panel). This result showed that
not only STAT1 phosphorylation but also nuclear translocation
of the phosphorylated STAT1 was down-regulated by NS5A
protein. To further demonstrate whether inhibition of nuclear
translocation of phosphorylated STAT1 might occur in the context
of HCV RNA replication, both cytosolic and nuclear fractions of
IFN-cured and HCV replicon cells prepared from either untreated
or treated with IFN-a were immunoblotted with anti-phospho-
STAT1 antibody. In the absence of IFN-a stimulation, phosphory-
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Fig. 1. HCV NS5A inhibits IFN-a induced ISRE reporter activity. (A) IFN-a-mediated transcriptional activation is inhibited by HCV NS5A protein of both genotype 1b and 2a.
Huh 7 cells were transfected with ISRE-luc reporter plasmid together with the indicated expression plasmids. At 24 h after transfection, cells were either left untreated or
treated with 500 U/ml of IFN-a for 12 h. Luciferase activities were determined and the values were normalized based on b-gal activities (upper panel). The data shown
represent duplicate experiments. Protein expressions of genotype 1b and 2a NS5A were veriﬁed by immunoblot analysis using anti-Myc monoclonal antibodies (lower panel).
(B) NS5A protein of both genotype 1b and 2a suppressed IFN-a induced ISRE reporter activities in a dose-dependent manner. Huh 7 cells were transfected with ISRE-luc
reporter plasmid together with the selected amounts (0.5, 1, and 2 lg) of HCV NS5A expression plasmid of either genotype 1b or 2a. At 24 h after transfection, cells were
either left untreated or treated with 500 U/ml of IFN-a for 12 h and then luciferase activities were determined. (C) Poly I:C-induced ISRE-luc reporter activity was reduced by
NS5A protein of both genotype 1b and 2a. Huh 7 cells were transfected with ISRE-luc reporter plasmid together with vector, 1b5A, 2a5A expression plasmid, individually in
the absence or presence of poly I:C (25 lg) transfection for 6 h. Cells were harvested and luciferase activities were measured. (D) Sendai virus-induced ISRE transcriptional
activity was inhibited by NS5A protein of both genotype 1b and 2a. Huh 7 cells were transfected as described in (C) and then infected with Sendai virus with m.o.i. of 3 for 6 h.
Luciferase activities were determined as described above. The data shown represent duplicate experiments.
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cells (Fig. 2C, lanes 1–4). Upon IFN-a stimulation, both cytosolic
and nuclear STAT1 protein levels were increased in IFN-cured cells
(Fig. 2C, lanes 5 and 7). We found that phosphorylated STAT1 level
in cytosolic fraction of HCV replicon was lower than that of IFN-
cured cells (Fig. 2C, lane 5 vs. lane 6). Furthermore, IFN-a-stimu-
lated nuclear translocation of STAT1 was remarkably decreased in
HCV replicon cells as compared with IFN-cured cells (Fig. 2C, lanes
6 and 8). Together, these data suggest that the inhibitory effect of
NS5A on IFN-a-induced immune response may be due to the inhi-
bition of phosphorylation and subsequent nuclear translocation of
STAT1 protein.3.3. NS5A derived from both genotype 1b and 2a inhibits IFN-
a-induced ISGs expressions
In response to viral infection, type I IFN induces activation of
STAT1 and stimulates the transcription of ISGs, which contain the
ISRE in the promoter regions [10,16]. To investigate the effects of
NS5A on the IFN-induced ISGs expression levels, stable cells
expressing vector, 1b NS5A, 2a NS5A, respectively, were treated
with IFN-a for the indicated time. Total cell lysates were immuno-
blotted with anti-ISGs protein antibodies. As shown in Fig. 3A, both
MxA and ISG15 proteins were highly expressed at 8 h after IFN-a
stimulation in vector stable cells and the expression levels of both
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Fig. 2. HCV NS5A protein inhibits IFN-a induced STAT1 phosphorylation and nuclear translocation. (A) IFN-a induced STAT1 phosphorylation was suppressed by HCV NS5A
protein in stable cells. Stable cells expressing either genotype 1b or 2a NS5A protein, or vector stable cells were treated with selected amounts (0, 50, 100, 200, 500, 1000 U/
ml) of IFN-a for 12 h. Cells were harvested and the level of STAT1 phosphorylation was determined by immunoblotting with anti-phospho-STAT1 antibody. Protein
expression of GAPDH was used as a loading control for the same amount of cell lysates. (B) HCV NS5A protein inhibited IFN-a induced STAT1 phosphorylation and nuclear
translocation. Stable cells expressing either genotype 1b or 2a NS5A protein, or vector stable cells were either left untreated or treated with 500 U/ml of IFN-a for 12 h. Both
cytosolic and nuclear fractions were prepared and the level of STAT1 phosphorylation was determined by immunoblotting with anti-phospho-STAT1 antibody (1st panel).
The same cell lysates were analyzed for total STAT1 level by immunoblotting with anti-nonphospho-STAT1 antibody (2nd panel). Protein expression of NS5A was conﬁrmed
by immunoblotting with anti-Myc antibody (3rd panel). Both cytosolic and nuclear fractions were veriﬁed by immunoblot analysis using either anti-GAPDH (4th panel) or
B23 antibodies (5th panel). (C) IFN-a-induced STAT1 phosphorylation and nuclear translocation were inhibited by HCV subgenomic replicon. Huh7 cells harboring HCV
replicon and IFN-cured cells were either left untreated or treated with 500 U/ml of IFN-a for 12 h. Both cytosolic and nuclear fractions were prepared and the levels of both
total and phosphorylated STAT1 were determined as described in (B). C, IFN-cured cells; R, HCV subgenomic replicon cells.
4072 S.-M. Kang et al. / FEBS Letters 584 (2010) 4069–4076
0     1      2     4      8     12    24    
MxA
ISG15
PKR
STAT1
GAPDH
0     1      2     4      8     12    24    0      1     2     4      8     12    24 h IFN-α(1000U/ml)
2a5A stable1b5A stablevector stable
NS5A
MxA
ISG15
OAS2
IRF3
GAPDH
C CR R
IFN-α (-) IFN-α (+)
1                     2                    3               4 
Fig. 3. HCV NS5A inhibits IFN-a-induced ISGs expressions. (A) IFN-a-induced ISGs expressions were inhibited by HCV NS5A protein. Stable cells expressing either genotype
1b or 2a NS5A protein, or vector stable cells were treated with 500 U/ml of IFN-a for the indicated time. Cells were harvested and protein expressions of ISGs were conﬁrmed
by immunoblotting with anti-MxA (1st panel), ISG15 (2nd panel), PKR (3rd panel), and STAT1 (4th panel) antibodies. GAPDH was used as a loading control (bottom panel). (B)
ISGs expressions were abrogated in HCV subgenomic replicon cells. Both IFN-cured and HCV subgenomic replicon cells were either left untreated or treated with 500 U/ml of
IFN-a for 12 h. Total cell lysates were immunoblotted with anti-NS5A (1st panel), MxA (2nd panel), ISG15 (3rd panel), and OAS2 (4th panel) antibodies. GAPDH was used as a
loading control.
S.-M. Kang et al. / FEBS Letters 584 (2010) 4069–4076 4073MxA and ISG15 proteins were continuously increased up to 24 h.
On the other hand, PKR was expressed as early as 1 h after IFN-a
stimulation in vector stable cells. It was striking that MxA, ISG15,
and PKR expressions were remarkably inhibited by both genotype
1b and 2a NS5A protein (Fig. 3A, middle and right panels). We
found that the expression level of STAT1 was not affected by
NS5A protein. These data indicate that NS5A inhibits ISGs expres-
sions through the inhibition of STAT1 phosphorylation. To further
investigate whether IFN-a-induced ISGs expressions were inhib-
ited in the context of HCV RNA replication, ISGs protein expression
levels in both IFN-cured and replicon cells were compared in the
absence or presence of IFN-a treatment. In the absence of IFN-a
stimulation, none of ISGs proteins were expressed (Fig. 3B, lanes
1 and 2). Upon IFN-a treatment, protein levels of ISGs, including
MxA, ISG15, and 20-50-oligoadenylate synthetase (OAS) were in-
creased in IFN-cured cells (Fig. 3B, lane 3). As expected, all ISGs
protein levels were drastically decreased in cells harboring HCV
replicon (Fig. 3B, lane 4). These data conﬁrmed that HCV counter-
acted IFN-induced signaling pathways by inhibiting ISGs protein
expressions.
3.4. Both intracellular and extracellular IL-8 levels are increased in
cells expressing NS5A protein derived from both genotype 1b and 2a
Since NS5A inhibits nuclear translocation of STAT1 and ISGs
expressions, mRNA microarray analysis was performed using
NS5A stable cells to investigate possible involvement of other reg-ulatory genes in IFN responses. Following IFN-a treatment for 12 h,
total mRNAs isolated from vector stable, 1b NS5A stable, and 2a
NS5A stable cells, respectively were subjected to microarray anal-
ysis. Supplementary Fig. 2 is the summary of selected genes from
microarray data. Interestingly, IL-8 level was highly increased in
both genotype 1b and 2a NS5A stable cells as compared with vec-
tor stable cells (3.94- and 4.17-fold increase, respectively). IL-8 is a
key component of innate immune response because IL-8 inhibits
ISGF3 complexes of STAT1, STAT2, and IRF9 [17]. When ISGF3 fails
to function properly, the cellular level of IL-8 is increased. It has
been previously reported that CXCL-8/IL-8 induction was regulated
by HCV infection [18]. To examine whether IL-8 level was regu-
lated by NS5A protein, Huh7 cells transfected with the control vec-
tor, 1b NS5A, and 2a NS5A expression plasmid, individually were
immunoblotted with anti-IL-8 antibody. Indeed, IL-8 protein levels
were highly increased in cells expressing both genotypes 1b and 2a
NS5A protein (Supplementary Fig. 3, lanes 3 and 4) as compared
with control vector cells.
We then determined the extracellular IL-8 level in NS5A stable
cells. Culture supernatants collected from either vector stable or
NS5A stable cells were concentrated with Centricon and then IL-
8 protein levels were determined by enzyme-linked immmunosor-
bent assay (ELISA) kit. As shown in Fig. 4, IL-8 production was in-
creased 2- to 3-fold at 12 h and 4- to 5-fold at 24 h in both
genotypes 1b and 2a NS5A stable cells as compared with vector
stable cells (left panel). MTT data indicated that cell viability was
not affected by both genotypes 1b and 2a NS5A (Fig. 4, right panel).
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in cells transiently expressing either genotype 1b or 2a NS5A pro-
tein (Supplementary Fig. 4). Since cell viability was not affected by
NS5A protein, the increase of IL-8 production was not due to cell
damage (Supplementary Fig. 4, right panel). To determine the re-
gion in NS5A that is responsible for IL-8 induction, various deletion
mutants of NS5A (Supplementary Fig. 5A) were transiently ex-
pressed in Huh7 cells and then IL-8 production was measured by
using an IL-8 speciﬁc ELISA kit. As shown in Supplementary
Fig. 5B, IL-8 production was increased 14-fold in wild-type
NS5A as compared with vector control. IL-8 productions in both
middle- and C-terminal NS5A mutants maintained basal levels as
in the vector control. However, IL-8 production was increased
8-fold in cells expressing N-terminal region of NS5A protein, indi-
cating that N-terminal region of NS5A mediated IL-8 production.
To further demonstrate whether the N-terminal NS5A protein
could block ISRE transcription, we performed ISRE transcription as-
say using various deletion mutants of NS5A (Supplementary
Fig. 5A). As shown in Supplementary Fig. 5C, N-terminal NS5A pro-
tein, but not middle and C-terminal NS5A, blocked ISRE activity.
This further conﬁrms that the N-terminal NS5A conferred IFN-a-
induced antiviral immune responses.
3.5. IL-8 augments the inhibitory effect of NS5A protein on IFN-a-
induced ISRE reporter activity
To investigate whether NS5A-induced IL-8 production was in-
volved in JAK-STAT pathway, Huh7 cells expressing NS5A protein
were treated with IFN-a, further incubated with IL-8, and then
ISRE-luc reporter activity was determined. As shown in Fig. 5A,
IFN-a-induced ISRE reporter activity was decreased by both geno-
type 1b and 2a NS5A protein. The inhibitory function was en-
hanced by IL-8 in a dose-dependent manner in both genotypes.
Next, we determined the effect of IL-8 on IFN-a-induced antiviral
activity of NS5A protein. Stable cells expressing either vector or
genotype 1b NS5A protein were treated with IFN-a in the absence
or presence of IL-8, and total cell lysates were immunoblotted with
anti-ISG15 antibody. Fig. 5B showed that ISG15 protein expression
level in vector stable cells was increased by IFN-a in a dose-depen-
dent manner (Fig. 5B, left panel); whereas, IFN-a-induced ISG15
expression was inhibited by NS5A protein (Fig. 5B, middle panel).
Moreover, inhibition of IFN-a-induced ISG expression was signiﬁ-
cantly enhanced by addition of IL-8 in cells expressing NS5A pro-
tein (Fig. 5B, right panel). We found the similar results using
stable cells expressing NS5A protein derived from genotype 2a
(data not shown). These in vitro data further imply that some host
factor may be involved in genotypic differences of IFN antagonism
in HCV patients.IL
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To verify the role of IL-8 in the anti-IFN response of NS5A, Huh7
cells transfected with siRNA targeting two different sites of IL-8
were treated with IFN-a and then luciferase activities were deter-
mined. As shown in Supplementary Fig. 6, anti-IFN activity of NS5A
was abrogated by knockdown of IL8 with siRNA. It is noteworthy
that each siRNA alone targeting different site of IL8 nulliﬁed the
inhibitory effect of NS5A, demonstrating that IL-8 produced by
NS5A played an important role in anti-IFN activity.
4. Discussion
Patients infected with HCV genotype 1 had lower SVR rate to
IFN than those infected with genotype 2 or 3. Current combination
therapy using pegylated IFN-a plus ribavirin for the majority of
genotypes 2 or 3 results in a SVR, whereas only 50% of patients in-
fected with genotype 1 attain SVR. However, the underlying mech-
anisms of HCV to IFN resistance are not clearly understood.
Modulations of IFN signaling by HCV proteins have been re-
ported previously. HCV proteins inhibit IFN-a-induced JAK-STAT
pathway in the liver of transgenic mice [19]. Among the HCV viral
proteins, NS5A and E2 proteins disrupted the normal IFN-a-in-
duced antiviral activities by interaction with PKR [5,7]. Both HCV
core and NS5A proteins inhibited IFN-a-induced JAK-STAT signal
pathway by interaction with STAT1 protein [20]. Since IFN resis-
tance has been controversial depends on HCV genotypes of NS5A,
we extensively compared IFN-a-induced ISRE activities between
genotype 1b and 2a NS5A using Poly I:C and Sendai virus as well
as IFN treatment. We demonstrated that IFN-a-induced ISRE re-
porter activity was inhibited by both genotype 1b and 2a NS5A.
Furthermore, NS5A proteins derived from both genotypes inhibited
ISRE-luc reporter activity in a dose-dependent manner in Huh7
cells. It was noteworthy that genotype 1b NS5A inhibited ISRE-
luc reporter activity slightly, but not signiﬁcantly, more than 2a
NS5A. Both Poly I:C and Sendai virus are known to stimulate IFN
signaling pathways. In fact, we showed that both Poly I:C- and Sen-
dai virus-induced ISRE transcriptional activities were also inhibited
by NS5A protein. However, the differences of inhibitory function
between two genotypes of NS5A protein on Poly I:C- and Sendai
virus-induced ISRE gene expressions were indistinguishable from
each other. Collectively, these results suggest that HCV NS5A, irre-
spective of its genotype, speciﬁcally inhibits IFN-a-, Sendai virus-,
and poly I:C-induced ISRE-luc reporter activities.
To see if there is any difference in IFN-a signaling between two
genotypes, we determined IFN-a-induced phosphorylated STAT1,
an active form of STAT1, protein level in cells expressing either
1b or 2a NS5A protein. Indeed, IFN-a-induced STAT1 phosphoryla-Ce
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Fig. 5. IL-8 promotes the inhibitory effect of NS5A protein on IFN-a-induced immune response. (A) IL-8 potentiates inhibitory effect of NS5A protein on IFN-a induced ISRE
reporter activity. Huh7 cells were cotransfected with ISRE-luc reporter plasmid together with 0.5 lg of either 1b NS5A or 2a NS5A expression plasmid. At 24 h after
transfection, cells were either left untreated or treated with 500 U/ml of IFN-a for 18 h, and then incubated with the selected amounts (0, 15, 30, and 45 ng/ml) of human IL-8
for 6 h. The data shown represent triplicate experiments. (B) IL-8 enhances the antiviral activity of NS5A protein. Stable cells expressing either vector or genotype 1b NS5A
protein were treated with increasing amounts of IFN-a (0, 50, 100, 200, 500, 1000 U/ml) for 12 h in the absence or presence of IL-8 for 12 h. Total cell lysates were
immunoblotted with anti-ISG15 antibody. GAPDH was used as a loading control.
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ilar extent. Consequently, both genotypes of NS5A strongly inhib-
ited translocation of the phosphorylated STAT1. We further
demonstrated that IFN-a-induced phosphorylated STAT1 and nu-
clear translocated STAT1 levels were signiﬁcantly decreased in
HCV replicon cells as compared with IFN-cured cells. We then
determined the effects of NS5A on the IFN-induced ISG family pro-
tein expression levels. We showed that ISG protein levels were
remarkably decreased in stable cells expressing both 1b and 2a
NS5A protein. We further demonstrated that ISG protein expres-
sion levels were drastically inhibited in HCV replicon cells. These
data indicate that both genotypes of NS5A counteract IFN signaling
by inhibiting STAT1 phosphorylation and subsequent ISG family
protein expressions. Recently, Garaigorta and Chisari [21] reported
that HCV-induced PKR activation suppressed the ISG proteins in
HCV-infected cells. This study demonstrated that the activation
of PKR by HCV actually gave the positive effect on HCV in antiviral
effects of IFN. Of interest, the activation of PKR by HCV was shown
to be beneﬁcial to HCV replication. In PKR-downregulated cells,
IFN-stimulated MxA and ISG15 protein expression in HCV-infected
cells were restored to the level in uninfected cells. This was respon-
sible for the resistance of HCV to the antiviral effects of IFN.
CXCL-8/IL-8 is known to have important roles in tumor necrosis,
cell survival, proliferation and innate immune responses [22].
Previous studies have demonstrated that the HCV structural pro-
teins induce IL-8 [23], and NS5A protein is also able to inhibit
the IFN responses partially by inducing IL-8 [24]. Indeed, both
microarray and immunoblot data in our studies showed that IL-8
levels were highly increased in cells expressing both genotypes
1b and 2a NS5A protein. Furthermore, IL-8 production in cell cul-
ture supernatant was also increased by both genotype 1b and 2a
NS5A protein of stable cells as compared with vector stable cells.
We suggest that N-terminal region of NS5A protein confers
IFN-a-induced antiviral immune response because this regionmediates the IL-8 production. It has been previously reported that
the increase of IL-8 level resulted in the decline of IFN-regulated
immune response [23,24]. Indeed, inhibition of IFN-a-induced ISRE
reporter activity by both genotype 1b and 2a NS5A protein was sig-
niﬁcantly increased by IL-8, and this result was further conﬁrmed
by inhibition of IFN-a-induced ISG15 expression level by IL-8 in
NS5A stable cells. In addition, the involvement of ISDR of NS5A
in HCV antiviral responses has been contradictory in many studies.
In our study, ISDR localized in the middle region was not involved
in anti-IFN effect of NS5A. Of interest, IL-8 induced by N-terminal
region of NS5A augmented the anti-IFN effect of NS5A.
Collectively, we demonstrated that IFN antagonism by NS5A
protein was mediated through STAT1 signaling transducer and this
effect was enhanced by IL-8. We demonstrated that not only geno-
type 1b but also genotype 2a NS5A exerted IFN-a-induced antiviral
activity. However, genotypic differences in IFN antagonism
between genotype 1b and 2a NS5A were not signiﬁcant as opposed
to previous report [25]. Our in vitro data imply that some other
host factors, other HCV proteins, and host genetics such as IL28B
may be implicated in genotype differences in IFN responses of
HCV patients. Nevertheless, NS5A appears to play the crucial role
in the viral evasion from host innate immune response and thus
contribute to persistence and pathogenesis of HCV-induced liver
disease.
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